I have a creatine‑kinase level of 334 U/L while taking rosuvastatin 10 mg daily; what does this indicate and how should I manage it?

Management of CK 334 U/L on Rosuvastatin 10 mg

Continue rosuvastatin 10 mg without interruption, as this CK level (approximately 3× the upper limit of normal) does not require dose modification or discontinuation in an asymptomatic patient. 1, 2

Immediate Assessment Required

Ask the patient directly about muscle symptoms right now:

• Muscle pain, soreness, tenderness, or weakness (especially in thighs, shoulders, or back) 1, 3
• Recent changes in exercise intensity or strenuous physical activity 1
• Dark or cola-colored urine 2
• Timing of any symptoms relative to starting rosuvastatin 1

Management Based on Symptom Status

If Asymptomatic (No Muscle Symptoms)

Continue rosuvastatin 10 mg at the current dose without modification. 4, 1, 2

• CK elevations <4× ULN in asymptomatic patients do not require statin discontinuation 4, 1
• The European Society of Cardiology specifically recommends maintaining therapy when CK is approximately 3× ULN without symptoms 1
• Recheck CK in 4-6 weeks to ensure it is not rising 4, 2
• Educate the patient to report immediately if muscle pain, weakness, or dark urine develops 4, 3

If Symptomatic (Muscle Pain/Weakness Present)

Discontinue rosuvastatin immediately and monitor CK weekly until normalization. 4, 1, 3

• Any CK elevation with muscle symptoms warrants stopping the statin 4, 3
• Follow CK levels weekly until they normalize and symptoms resolve 4, 1
• After complete resolution (typically 2-6 weeks), rechallenge with a lower-risk statin such as pravastatin or fluvastatin at the lowest dose 4, 1
• Consider alternate-day dosing of rosuvastatin or atorvastatin if rechallenge is needed 4

Essential Laboratory Workup Now

Obtain these tests immediately to identify contributing factors: 1, 2

• Thyroid-stimulating hormone (TSH) – hypothyroidism dramatically increases myopathy risk and is a common missed diagnosis 1, 2, 3
• Serum creatinine – renal impairment increases statin levels and myopathy risk 1, 3
• Vitamin D (25-OH) – deficiency increases muscle symptom risk 1
• ALT and AST – to assess hepatic function 1, 2

Critical Thresholds to Remember

• CK <4× ULN + asymptomatic = Continue statin, recheck in 4-6 weeks 4, 1
• CK 4-10× ULN + symptoms = Stop statin, monitor CK weekly 4, 3
• CK >10× ULN (>2000 U/L) = Stop statin immediately regardless of symptoms, risk of rhabdomyolysis 4, 1, 3

Rosuvastatin-Specific Considerations

Rosuvastatin 10 mg is appropriate for this patient's renal function. 4

• The KDOQI guidelines state that rosuvastatin requires no dose adjustment for mild to moderate kidney disease 4
• Only when creatinine clearance <30 mL/min should rosuvastatin be limited to 5 mg daily and not exceed 10 mg daily 4
• Female gender, older age, and higher doses increase myopathy risk with rosuvastatin 1, 3

Common Pitfalls to Avoid

• Do not routinely monitor CK in asymptomatic patients – this provides little clinical value and leads to unnecessary statin discontinuation 1, 2
• Do not stop statins for CK <10× ULN without symptoms – this removes cardiovascular protection without clear benefit 4, 1
• Do not dismiss normal CK in symptomatic patients – muscle symptoms can occur without CK elevation 1, 2
• Do not overlook hypothyroidism – always check TSH in any patient with elevated CK on statins 1, 2, 3
• Do not forget to ask about recent exercise – transient CK rises from exertion are common and unrelated to statin toxicity 4, 1

If Statin Must Be Stopped

Add ezetimibe 10 mg daily immediately to maintain lipid control while rosuvastatin is held. 1

• After symptoms resolve and CK normalizes, rechallenge with pravastatin or fluvastatin at low doses 4, 1
• Consider bempedoic acid as an alternative, as it is not activated in muscle tissue 1